[Susceptibility to antibiotics and drug metabolism in patients with H. pylori infection refractory to the initial treatment--therapeutic strategy based on susceptibility to CAM and CYP2C19 polymorphism].
Furuta
Takahisa
T
First Department of Medicine, Hamamatsu University School of Medicine.
Sugimoto
Mitsushige
M
Nakamura
Akiko
A
Shirai
Naohito
N
D000658:Amoxicillin / Q000008:administration & dosage; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D017291:Clarithromycin / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology*; D065731:Cytochrome P-450 CYP2C19; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D000658:Amoxicillin; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D017291:Clarithromycin